Skip to Content
Merck

Key Documents

View All Documentation

239763-M

Cycloheximide

Cycloheximide, CAS 66-81-9, is an antifungal antibiotic that inhibits protein synthesis in eukaryotes but not prokaryotes.

Synonym(s):

Cycloheximide

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C15H23NO4
CAS Number:
66-81-9
Molecular Weight:
281.35
UNSPSC Code:
12352111
NACRES:
NA.77
MDL number:
MFCD00082346
Assay:
≥90% (by assay)
Form:
powder
Quality level:
200
Storage condition:
OK to freeze
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

200

assay

≥90% (by assay)

form

powder

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze

color

white to brown

storage temp.

room temp

SMILES string

N1C(=O)CC(CC1=O)C[C@@H](O)[C@@H]2C[C@H](C[C@@H](C2=O)C)C

InChI

1S/C15H23NO4/c1-8-3-9(2)15(20)11(4-8)12(17)5-10-6-13(18)16-14(19)7-10/h8-12,17H,3-7H2,1-2H3,(H,16,18,19)/t8-,9-,11-,12+/m0/s1

InChI key

YPHMISFOHDHNIV-FSZOTQKASA-N

General description

An antifungal antibiotic that inhibits protein synthesis in eukaryotes but not in prokaryotes. Interacts directly with the translocase enzyme, interfering with the translocation step. Inhibits cell-free protein synthesis in eukaryotes. Competitively inhibits hFKBP12 (Ki = 3.4 µM). Triggers apoptosis in HL-60 cells, T-cell hybridomas, Burkitt′s lymphoma cells, and a variety of other cell types, including rodent macrophages. Induces DNA fragmentation in macrophages, however it inhibits DNA cleavage in rat thymocytes treated with thapsigargin, methylprednisolone, and ionomycin. Rapidly destroyed in alkaline solutions.

Other Notes

Christner, C., et al. 1999. J. Med. Chem.42, 3615.
Lu, Q. and Mellgreen,R.L. 1996. Arch. Biochem. Biophys.334, 175.
Chow, S.C., et al. 1995. Exp. Cell Res.216, 149.
Waring, P. 1990. J. Biol. Chem.265, 14476.
Obrig, T.G., et al. 1971. J. Biol. Chem.246, 174.
Pestka, S. 1971. Annu. Rev. Microbiol.25, 487.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Highly Toxic & Carcinogenic / Teratogenic (I)

Still not finding the right product?

Explore all of our products under Cycloheximide

signalword

Danger

Hazard Classifications

Acute Tox. 2 Oral - Aquatic Chronic 2 - Muta. 2 - Repr. 1B

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

66-81-9

CAS No.

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Wenxin Zhang et al.
Acta pharmaceutica Sinica. B, 13(6), 2585-2600 (2023-07-10)
Mevalonate metabolism plays an important role in regulating tumor growth and progression; however, its role in immune evasion and immune checkpoint modulation remains unclear. Here, we found that non-small cell lung cancer (NSCLC) patients with higher plasma mevalonate response better
Zhan Liu et al.
Cell death discovery, 10(1), 298-298 (2024-06-23)
LIMA1 is a LIM domain and Actin binding 1 protein that acts as a skeleton protein to promote cholesterol absorption, which makes it an ideal target for interfering with lipid metabolism. However, the detailed regulation of LIMA1 remains unclear. Here
Ling Ding et al.
The Journal of clinical investigation, 133(1) (2023-01-04)
Understanding the regulatory mechanisms of PD-L1 expression in tumors provides key clues for improving immune checkpoint blockade efficacy or developing novel oncoimmunotherapy. Here, we showed that the FDA-approved sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin dramatically suppressed PD-L1 expression and enhanced T
View All Related Papers